IQVIA Expands Partnership with Veeva for Clinical Operations Applications

IQVIA and Veeva Systems Expand Their Strategic Collaboration

In a significant development in the world of clinical research, IQVIA (NYSE: IQV) has announced the enhancement of its partnership with Veeva Systems (NYSE: VEEV) by selecting Veeva's Clinical Trial Management System (CTMS), electronic Trial Master File (eTMF), Study Startup, and Site Connect as standard enterprise applications. This move will empower IQVIA's clinical development studies worldwide, building on their previous partnership that focused on Electronic Data Capture (EDC).

The collaboration combines the robust capabilities of both organizations, offering cutting-edge solutions designed to enhance clinical trial efficiency. This partnership aims to streamline operations and improve site centrality, ultimately facilitating more informed decision-making processes. This will accelerate patient access to groundbreaking treatments as well as enhance the overall clinical trial experience.

Richard Staub, president of Research and Development Solutions at IQVIA, commented, "By aligning our companies' strengths, we provide clinical teams with a more integrated way to work together, driven by seamless technology.” He noted the flexibility provided to clients in selecting the best technologies and solutions that match their needs, emphasizing IQVIA's innovative capabilities within the mix.

Peter Gassner, CEO and founder of Veeva, expressed excitement about the growth of their partnership, highlighting its focus on innovation and user success. He stated, “This is an exciting development for our collaboration with IQVIA, and we are dedicated to enabling smoother integrations of products and services for our clients, improving patient access to innovations.” To learn more about their collaborative efforts and advancements, attendees can connect with IQVIA and Veeva representatives at the Veeva RD and Quality Summit scheduled for October 20-21 in Boston.

About IQVIA

IQVIA is recognized as a leading global provider of clinical research services, commercial insights, and health information for life sciences and healthcare sectors. The organization's solution portfolio is empowered by what they call IQVIA Connected Intelligence™, delivering actionable insights and services derived from high-quality health data, advanced analytics, Artificial Intelligence (AI), and extensive industry expertise.

Approximately 94,000 employees across more than 100 countries, including experts in health, life sciences, data science, technology, and operational excellence, drive IQVIA's commitment towards accelerating the development and commercialization of innovative medical treatments. Their mission is to enhance patient outcomes and foster public health on a global scale.

Moreover, IQVIA leads the industry in preserving patient privacy. The company employs a comprehensive array of technologies and protective measures designed to maintain individuals' privacy while generating and analyzing large-scale data that helps health sector stakeholders identify trends and correlate treatment methods with optimal outcomes.

Their expertise supports biotech and pharmaceutical companies, medical researchers, government agencies, and payers in gaining deeper insights into diseases and advancements in scientific progress—advancing the path to healing.

For more information about IQVIA, visit www.iqvia.com.

About Veeva Systems

Veeva Systems offers a leading cloud-based platform dedicated to the life sciences sector, encompassing applications, data management, and consulting services. With a strong commitment to innovation and customer success, Veeva serves more than 1,500 clients, including the largest global biopharmaceutical companies and emerging biotech firms. Veeva places great importance on balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries they serve.

For additional information on Veeva Systems, please visit veeva.com.

Conclusion

As IQVIA and Veeva Systems continue their collaborative journey, stakeholders and clients alike can expect enhanced operational efficiencies in clinical trials, paving the groundwork for groundbreaking advancements in medical treatments. The ongoing commitment to innovation and patient-centric approaches signifies a promising future for clinical operations in the life sciences domain.